Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer.
暂无分享,去创建一个
D. Brizel | R. Sauer | T. Wasserman | W. Oster | J. Mackowiak | J. Zhang | P. Peeples
[1] R. Lennox,et al. PCD13: PATIENT BENEFIT QUESTIONNAIRE (PBQ) FOR XEROSTOMIA: DEVELOPMENT AND VALIDATION REPORT , 1999 .
[2] M. Ajax,et al. PCD12: COST OF MANAGING MUCOSITIS AND XEROSTOMIA IN HEAD AND NECK CANCER PATIENTS UNDERGOING CHEMORADIOTHERAPY (CRT) OR RADIATION (RT) , 1999 .
[3] T. Bodenheimer,et al. The American health care system--the movement for improved quality in health care. , 1999, The New England journal of medicine.
[4] D. Brizel,et al. 6 Final report of a phase III randomized trial of amifostine as a radioprotectant in head and neck cancer , 1999 .
[5] Taylor Murray,et al. Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.
[6] J. Dwyer,et al. Nutritional implications of dental and swallowing issues in head and neck cancer. , 1998, Oncology.
[7] J. Büntzel,et al. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] M. Synodinou,et al. The prophylactic use of amifostine in the prevention of chemoradiation induced mucositis and xerostomia in head and neck cancer , 1998 .
[9] D. Brizel,et al. Randomized phase III trial of radiation±Ethyol® (Amifostine) in patients with head and neck cancer , 1997 .
[10] A. Laviano,et al. Nutritional issues in cancer management. , 1996, Nutrition.
[11] Ganley Bj. Effective mouth care for head and neck radiation therapy patients. , 1995 .
[12] S. McDonald,et al. Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction. , 1994, International journal of radiation oncology, biology, physics.
[13] J. Rieke,et al. A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] R. Little. Pattern-Mixture Models for Multivariate Incomplete Data , 1993 .
[15] P. Fox,et al. Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction , 1993, Cancer.
[16] B. Baum,et al. How Much Saliva is Enough , 1991 .
[17] P. Fox,et al. Subjective reports of xerostomia and objective measures of salivary gland performance. , 1987, Journal of the American Dental Association.
[18] H. Niibe,et al. Clinical study of the radioprotective effects of Amifostine (YM-08310, WR-2721) on chronic radiation injury. , 1986, International journal of radiation oncology, biology, physics.
[19] W. Goodwin,et al. The value of the prognostic nutritional index in the management of patients with advanced carcinoma of the head and neck. , 1984, Head & neck surgery.
[20] M. Moore. The effect of radiation on connective tissue. , 1984, Otolaryngologic clinics of North America.
[21] J. Ware,et al. Random-effects models for longitudinal data. , 1982, Biometrics.